EXELIXIS, INC. (EXEL)
EXELIXIS, INC. (EXEL) from its SEC filings: 2025 revenue $2.3 billion (+7% vs the year before), net margin 34%, free cash flow $875.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $2.3 billion |
| Revenue growth | +7% |
| Net income | $782.6 million |
| Net margin | 33.7% |
| Free cash flow | $875.8 million |
| Diluted EPS | $2.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +11% |
| Cash | $281.4 million |
| Long-term debt | $0 |
| Share count, 1 year | -8% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.